Literature DB >> 22449226

A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma.

Yasunori Enomoto1, Takahiko Kasai, Maiko Takeda, Masato Takano, Kouhei Morita, Eiji Kadota, Norishige Iizuka, Hiroshi Maruyama, Joji Haratake, Yu Kojima, Naoya Ikeda, Akitaka Nonomura.   

Abstract

An evaluation of epidermal growth factor receptor (EGFR) phenotypic expression in malignant pleural and peritoneal mesothelioma was undertaken, using immunohistochemical (IHC) and fluorescence in situ hybridization (FISH) analysis. Thirty-eight malignant mesothelioma (MM) specimens were subjected to IHC staining and FISH to evaluate the expression of EGFR protein and gene status. Overall positive IHC reaction was detected in 20/38 (53%) cases, in 11/22 (50%) pleural MM, and in 9/16 (56%) peritoneal MM. Our study confirmed that EGFR membranous expression is a common feature in MM, but not in benign mesothelial lesion. Thirty-seven cases did not show a gene copy number gain. Only one case showed a copy number gain. The protein overexpression of EGFR was not related to a gene copy number gain.
© 2012 The Authors. Pathology International © 2012 Japanese Society of Pathology and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22449226     DOI: 10.1111/j.1440-1827.2011.02778.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  8 in total

1.  DNA copy number gains in malignant pleural mesothelioma.

Authors:  Masashi Furukawa; Shinichi Toyooka; Tatsuro Hayashi; Hiromasa Yamamoto; Nobukazu Fujimoto; Junichi Soh; Shinsuke Hashida; Kazuhiko Shien; Hiroaki Asano; Keisuke Aoe; Kazunori Okabe; Harvey I Pass; Kazunori Tsukuda; Takumi Kishimoto; Shinichiro Miyoshi
Journal:  Oncol Lett       Date:  2015-08-27       Impact factor: 2.967

2.  Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.

Authors:  Alain C Borczuk; Jianming Pei; Robert N Taub; Brynn Levy; Odelia Nahum; Jinli Chen; Katherine Chen; Joseph R Testa
Journal:  Cancer Biol Ther       Date:  2016-02-06       Impact factor: 4.742

3.  Leser–Trélat syndrome in malignant mesothelioma and pulmonary adenocarcinoma: is the EGFR pathway part of the syndrome?

Authors:  Rikke Karlin Jepsen; Anne Guldhammer Skov; Birgit Guldhammer Skov
Journal:  Virchows Arch       Date:  2014-01       Impact factor: 4.064

4.  BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.

Authors:  Hakan Alakus; Shawn E Yost; Brian Woo; Randall French; Grace Y Lin; Kristen Jepsen; Kelly A Frazer; Andrew M Lowy; Olivier Harismendy
Journal:  J Transl Med       Date:  2015-04-16       Impact factor: 5.531

Review 5.  Heterogeneity in Malignant Pleural Mesothelioma.

Authors:  Kathrin Oehl; Bart Vrugt; Isabelle Opitz; Mayura Meerang
Journal:  Int J Mol Sci       Date:  2018-05-30       Impact factor: 5.923

6.  Significance of EGFR and PTEN Expression and PLR and NLR for Predicting the Prognosis of Epithelioid Malignant Peritoneal Mesothelioma.

Authors:  Yufei Liang; Guoqi Zheng; Wenjie Yin; Hui Song; Chunying Li; Liang Tian; Dongliang Yang
Journal:  Gastroenterol Res Pract       Date:  2019-02-04       Impact factor: 2.260

7.  Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo.

Authors:  Zhi-Ran Yang; Zhi-Gao Chen; Xue-Mei Du; Yan Li
Journal:  Front Oncol       Date:  2020-12-07       Impact factor: 6.244

8.  Establishment and histopathological study of patient-derived xenograft models and primary cell lines of epithelioid malignant peritoneal mesothelioma.

Authors:  Zhi-Ran Yang; Zhi-Gao Chen; Zhong-He Ji; Yu-Lin Lin; Jue Zhang; Ru Ma; Zhao Li; Xi Jiang; Qian Chen; Xue-Mei Du; Yan Li
Journal:  Exp Anim       Date:  2021-01-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.